FDA Rejects Generic Tablets Larger Than Brand Citing Safety And Efficacy Concerns
Executive Summary
FDA denies ANDAs for one product because the generic tablet size is larger than the brand; the agency plans to release a draft guidance on generic equivalency to the reference listed drug in size, taste and smell.
You may also be interested in...
Generic Firms Fear FDA Pill Size Guidance Helps Brands Stifle Competition
FDA final guidance excludes attachment on capsules but otherwise is virtually identical to draft; GPhA had argued for flexibility in product design to avoid brand patents.
Generic Firms Fear FDA Pill Size Guidance Helps Brands Stifle Competition
FDA final guidance excludes attachment on capsules but otherwise is virtually identical to draft; GPhA had argued for flexibility in product design to avoid brand patents.
Generic Firms Fear 'New Lifecycle Management Tool' From FDA Pill Size Guidance
Final guidance excludes attachment on capsules but otherwise is virtually identical to draft; GPhA had argued for flexibility in product design to avoid brand patents.